20th Jun 2007 12:30
Notification of major interests in shares
20 June 2007
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:
Shire plc
2. Reason for the notification State Yes/No An acquisition or disposal of voting rights Yes An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached An event changing the breakdown of voting rights Other (please specify):
3. Full name of person(s) subject to the notification Dr. James Cavanaugh obligation:
(proxy holder) 4. Full name of shareholder(s) (if different from 3.): Shareholders
appointing Dr. James Cavanaugh as discretionary proxy holder
5. Date of the transaction (and date on which the 18 June 2007 threshold is crossed or reached if different): 6. Date on which issuer notified: 20 June 2007 7. Threshold(s) that is/are crossed or reached: 10% 8. Notified details:
A: Voting rights attached to shares
Class/type of Situation previous Resulting situation after the triggering shares to transaction if possible the Triggering using the ISIN transaction CODE Number Number Number Number of voting % of voting of of of rights rights Shares Voting shares Rights Direct Direct Indirect Direct Indirect 412,849 412,849 412,849 412,849 59,269,521 0.07 10.72
B: Financial Instruments
Resulting situation after the triggering transaction
Type of Expiration Exercise/ Number of voting % of financial date Conversion rights that may be voting instrument Period/ Date acquired if the rights instrument is exercised/converted Total (A+B) Number of voting rights % of voting rights 59,682,370 10.79
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:
Proxy Voting:10. Name of the proxy holder: Dr James Cavanaugh
11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will cease to hold voting 21 June 2007 rights: 13. Additional information: When proxy expires, 10.72% of voting rights will return to the shareholders that appointed Dr James Cavanaugh as discretionary proxy 14. Contact name: Vivienne Hemming, Deputy Company Secretary Shire plc
15. Contact telephone number: + 44 1256 894276
Annex Notification Of Major Interests In Shares
A: Identity of the person or legal entity subject to the notification obligation
Full name (including legal form for legal entities) Contact address (registered office for legal entities) Phone number Other useful information (at least legal representative for legal persons) B: Identity of the notifier, if applicable
Full name Dr James Cavanaugh Contact address Shire plc Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP Phone number +44 1256 894 276
Other useful information (e.g. functional Dr. James Cavanaugh is the relationship with the person or legal Non-Executive Chairman of Shire plc entity subject to the notification
obligation) C: Additional information
This notification is being made because Dr. James Cavanaugh, as Chairman of the meeting has been granted discretionary proxies for the AGM held on 20 June 2007.
T MayCompany Secretary
For further information please contact:
Investor Relations Clĩa Rosenfeld (Rest of the World) +44 1256 894 160 Eric Rojas (North America) +1 484 595 8252 Notes to editorsSHIRE PLC
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire's focused strategy is to develop and market products for specialty physicians. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company's website: www.shire.com.
1Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release
Registered in England 5492592Registered Office as above
SHIRE PLCRelated Shares:
Shire